ICAP-1 Inhibitors
ICAP-1 inhibitors belong to a specific class of chemical compounds designed to modulate cellular processes by targeting a key protein known as Integrin Cytoplasmic Domain-Associated Protein-1 (ICAP-1). ICAP-1 is a cytoplasmic protein that plays a crucial role in the regulation of integrin-mediated cell adhesion and signaling. Integrins are transmembrane receptors that facilitate cell adhesion to the extracellular matrix and mediate various cellular processes, including cell migration, proliferation, and differentiation. ICAP-1 interacts with the cytoplasmic tails of beta-integrin subunits, specifically β1 and β3, and acts as a negative regulator of integrin activation. By inhibiting ICAP-1, these compounds modulate the integrin function, ultimately impacting diverse cellular functions.
The mechanism of action of ICAP-1 inhibitors involves disrupting the interaction between ICAP-1 and integrin cytoplasmic tails, leading to enhanced integrin activation and altered signaling pathways. This alteration in integrin-mediated cellular processes has implications in various biological contexts, such as tissue development, immune responses, and wound healing. Researchers have been exploring the potential applications of ICAP-1 inhibitors in understanding fundamental cellular mechanisms and their involvement in various diseases.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits ICAP-1 by blocking the NF-κB pathway, preventing its translocation into the nucleus. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
BMS-345541 selectively inhibits ICAP-1 by targeting the IKKβ kinase and preventing NF-κB activation. | ||||||
SC514 | 354812-17-2 | sc-205504 sc-205504A | 5 mg 10 mg | $67.00 $91.00 | 13 | |
SC-514 inhibits ICAP-1 by specifically targeting IKK-2, an upstream kinase in the NF-κB signaling pathway. | ||||||
IMD 0354 | 978-62-1 | sc-203084 | 5 mg | $199.00 | 3 | |
IMD-0354 inhibits ICAP-1 by blocking IKKβ and preventing the phosphorylation of IκB, inhibiting NF-κB activation. | ||||||
Wedelolactone | 524-12-9 | sc-200648 sc-200648A | 1 mg 5 mg | $110.00 $337.00 | 8 | |
Wedelolactone inhibits ICAP-1 by blocking the phosphorylation of IκB and subsequent NF-κB activation. | ||||||
TPCK | 402-71-1 | sc-201297 | 1 g | $182.00 | 2 | |
TPCK inhibits ICAP-1 by targeting the proteasome and preventing the degradation of IκB, inhibiting NF-κB activation. | ||||||
IKK 16 | 1186195-62-9 | sc-204009 sc-204009A | 10 mg 50 mg | $223.00 $942.00 | 2 | |
IKK-16 is a selective IKK inhibitor that prevents ICAP-1 activation by blocking the IKKβ kinase. | ||||||
CDDO Imidazolide | 443104-02-7 | sc-504719 | 1 mg | $700.00 | ||
CDDO-Imidazolide inhibits ICAP-1 by blocking the activation of IKKβ and subsequent NF-κB signaling. | ||||||